Blue Trust Inc. Acquires 4,346 Shares of Sanofi (NASDAQ:SNY)

Blue Trust Inc. grew its holdings in Sanofi (NASDAQ:SNY) by 31.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 18,046 shares of the company’s stock after purchasing an additional 4,346 shares during the quarter. Blue Trust Inc.’s holdings in Sanofi were worth $1,040,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. POM Investment Strategies LLC bought a new position in shares of Sanofi during the 2nd quarter worth approximately $25,000. Register Financial Advisors LLC purchased a new stake in Sanofi during the 1st quarter worth approximately $29,000. Larson Financial Group LLC grew its position in Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after purchasing an additional 500 shares during the last quarter. Palisade Asset Management LLC purchased a new stake in Sanofi during the 1st quarter worth approximately $31,000. Finally, Arrow Financial Corp purchased a new stake in Sanofi during the 2nd quarter worth approximately $35,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $54.93 on Monday. The company’s fifty day moving average price is $56.11 and its 200 day moving average price is $51.58. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97. The company has a market capitalization of $139.12 billion, a PE ratio of 27.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. During the same period in the prior year, the firm posted $0.95 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, research analysts predict that Sanofi will post 4.26 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Finally, Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.